Our linear MR analyses showed no causal role of genetically predicted plasma cystatin C concentrations in CVDs (odds ratio [OR]: 0.96 per SD increment of plasma cystatin C; 95% CI = 0.90–1.03; p = 0.27), including stroke (OR: 0.96 per SD increment of cystatin C; 95% CI = 0.93–1.01), MI (OR: 0.97 per SD increment of cystatin C; 95% CI = 0.91–1.03), and CVD mortality (OR: 0.98 per SD increment of cystatin C; 95% CI = 0.96–1.01) (Figure 3). This evidence concerns the gene CST3 and stroke disorder.